{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:59Z","timestamp":1791868979227,"version":"4.3.4"},"reference-count":175,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.blre.2008.03.009","type":"journal-article","created":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T18:31:32Z","timestamp":1210098692000},"page":"261-281","source":"Crossref","is-referenced-by-count":146,"title":["Immunodeficiency-associated lymphomas"],"prefix":"10.1016","volume":"22","author":[{"given":"Huy","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Nourse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2008.03.009_bib1","first-page":"3","article-title":"Immunological surveillance in neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Transplant Rev"},{"key":"10.1016\/j.blre.2008.03.009_bib2","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2008.03.009_bib3","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib4","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","article-title":"Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma","volume":"110","author":"Gandhi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib6","first-page":"106","article-title":"Malignant lymphomas in transplantation patients","volume":"1","author":"Penn","year":"1969","journal-title":"Transplant Proc"},{"key":"10.1016\/j.blre.2008.03.009_bib7","series-title":"Immunosurveillance, immunodeficiency and lymphoproliferations","author":"Oertel","year":"2002"},{"key":"10.1016\/j.blre.2008.03.009_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaci.2007.08.053","article-title":"Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee","volume":"120","author":"Geha","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2008.03.009_bib9","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.V97.6.1598","article-title":"Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program","volume":"97","author":"Filipovich","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/335256a0","article-title":"Transfer of a functional human immune system to mice with severe combined immunodeficiency","volume":"335","author":"Mosier","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.blre.2008.03.009_bib11","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V92.9.3018","article-title":"Somatic Fas mutations in non-Hodgkin\u2019s lymphoma: association with extranodal disease and autoimmunity","volume":"92","author":"Gronbaek","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35043058","article-title":"The many substrates and functions of ATM","volume":"1","author":"Kastan","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2008.03.009_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)80086-0","article-title":"Atm-deficient mice: a paradigm of ataxia telangiectasia","volume":"86","author":"Barlow","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.blre.2008.03.009_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hon.2900110304","article-title":"Epstein-Barr virus-related lymphomagenesis in a child with Wiskott-Aldrich syndrome","volume":"11","author":"Gulley","year":"1993","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ajcp\/94.3.338","article-title":"Clonal immunoglobulin gene rearrangement in nodular lymphoid hyperplasia of the gastrointestinal tract associated with common variable immunodeficiency","volume":"94","author":"Laszewski","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib16","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2004-08-3269","article-title":"SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells","volume":"105","author":"Dupre","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.19.1.657","article-title":"X-linked lymphoproliferative disease: a progressive immunodeficiency","volume":"19","author":"Morra","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2008.03.009_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P","article-title":"Malignant lymphoma in the X-linked lymphoproliferative syndrome","volume":"59","author":"Harrington","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2008.03.009_bib19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood-2004-07-2965","article-title":"Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy","volume":"105","author":"Milone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2003-12-4226","article-title":"Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice","volume":"104","author":"Bagley","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1040-8428(02)00116-6","article-title":"Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T\/NK-cell lymphoproliferative disease","volume":"44","author":"Kawa","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2008.03.009_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0140-6736(93)91413-G","article-title":"Correction of Duncan\u2019s syndrome by allogeneic bone marrow transplantation","volume":"342","author":"Williams","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.03.009_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.blre.2008.03.009_bib24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199012203232510","article-title":"Cancers complicating organ transplantation","volume":"323","author":"Penn","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib25","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood.V92.7.2294","article-title":"BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome","volume":"92","author":"Cesarman","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2008.03.009_bib27","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib28","first-page":"136","article-title":"Incidence and consequences of post-transplantation lymphoproliferative disorders","volume":"10","author":"Boubenider","year":"1997","journal-title":"J Nephrol"},{"key":"10.1016\/j.blre.2008.03.009_bib29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.510300314","article-title":"Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation","volume":"30","author":"Hezode","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2008.03.009_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000478-199803000-00004","article-title":"Epstein-Barr virus infections in children after transplantation of the small intestine","volume":"22","author":"Finn","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib32","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood.V91.8.3079.3079_3079_3083","article-title":"Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users","volume":"91","author":"Hale","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00007890-198804000-00011","article-title":"The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children","volume":"45","author":"Ho","year":"1988","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.03.009_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jcp.48.4.287","article-title":"Clinicopathologic implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients","volume":"48","author":"Thomas","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/00007890-199805150-00017","article-title":"Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines","volume":"65","author":"Beatty","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.03.009_bib36","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2008.03.009_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF00838050","article-title":"Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders","volume":"20","author":"Haque","year":"1998","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.blre.2008.03.009_bib38","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1073\/pnas.85.22.8693","article-title":"Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency","volume":"85","author":"Gratama","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2008.03.009_bib39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2141.2002.03887.x","article-title":"Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants","volume":"119","author":"Meijer","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2008.03.009_bib40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2008.03.009_bib41","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib42","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","article-title":"Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders","volume":"19","author":"Leblond","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib43","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.03.009_bib44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with Rituximab or Chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2008.03.009_bib45","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.03.009_bib46","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V85.2.552.552","article-title":"Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders","volume":"85","author":"Knowles","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/(SICI)1096-9896(199802)184:2<177::AID-PATH977>3.0.CO;2-C","article-title":"Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease","volume":"184","author":"Perera","year":"1998","journal-title":"J Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.onc.1200840","article-title":"Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53","volume":"14","author":"Kashanchi","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2008.03.009_bib49","doi-asserted-by":"crossref","unstructured":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant. 2002;17(Suppl 4):31\u201333, 35\u201336.","DOI":"10.1093\/ndt\/17.suppl_4.31-b"},{"key":"10.1016\/j.blre.2008.03.009_bib50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1432-2277.2003.tb00343.x","article-title":"A single-centre experience of post-renal transplant lymphoproliferative disorder","volume":"16","author":"Herzig","year":"2003","journal-title":"Transpl Int"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2008.03.009_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008372814223","article-title":"Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients","volume":"11","author":"Milpied","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib52","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"Gonz\u00e1lez-Barca","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2008.03.009_bib53","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood.V110.11.390.390","article-title":"Sequential Treatment with Rituximab and CHOP chemotherapy in B-cell PTLD - A new standard in Therapy?","volume":"110","author":"Trappe","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2006.06482.x","article-title":"Epstein-Barr virus T-cell immunity despite rituximab","author":"Nehring","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2008.03.009_bib55","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1600-6143.2004.00693.x","article-title":"Cellular immunity to epstein-barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease","volume":"5","author":"Savoldo","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2008.03.009_bib56","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.03.009_bib57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00007890-198505000-00001","article-title":"Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation","volume":"39","author":"Hanto","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.03.009_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib59","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib60","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JVI.78.4.1893-1902.2004","article-title":"Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas","volume":"78","author":"Feng","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2008.03.009_bib61","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib62","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib63","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1600-6143.2005.00854.x","article-title":"Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells","volume":"5","author":"Comoli","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2008.03.009_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002371-200407000-00007","article-title":"Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases","volume":"27","author":"Wilkie","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.blre.2008.03.009_bib65","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.03.009_bib66","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1470-2045(05)70171-6","article-title":"Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation","volume":"6","author":"Wynn","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib67","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib68","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1600-6143.2007.01796.x","article-title":"Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders","volume":"7","author":"Gandhi","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2008.03.009_bib69","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood.V83.9.2715.2715","article-title":"Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease","volume":"83","author":"Savoie","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib70","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/00007890-200109270-00006","article-title":"Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction","volume":"72","author":"Wagner","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2008.03.009_bib71","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood.V96.13.4055","article-title":"Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response","volume":"96","author":"Yang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib72","series-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"270","article-title":"Methotrexate-associated lymphoproliferative disorders","author":"Harris","year":"2001"},{"key":"10.1016\/j.blre.2008.03.009_bib73","unstructured":"Tran H, Cheung C, Gill D, et al. Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. Nat Clin Pract Oncol (in press)."},{"key":"10.1016\/j.blre.2008.03.009_bib74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-199920060-00002","article-title":"Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?","volume":"20","author":"Georgescu","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.blre.2008.03.009_bib75","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0002-9343(99)80160-0","article-title":"Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study","volume":"99","author":"Moder","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib76","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.1780400533","article-title":"Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2008.03.009_bib77","first-page":"238","article-title":"Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy","volume":"25","author":"Weinblatt","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2008.03.009_bib78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0896-8411(89)80010-1","article-title":"The risk of neoplasms in patients treated with cyclosporine A","volume":"2","author":"Cockburn","year":"1989","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2008.03.009_bib79","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9343(85)90242-6","article-title":"Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland","volume":"78","author":"Hakulinen","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.2005.044784","article-title":"Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis","volume":"65","author":"Franklin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2008.03.009_bib83","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood.V97.10.3205","article-title":"Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma","volume":"97","author":"Matsuo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2005-04-1567","article-title":"Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas","volume":"108","author":"Niclot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib85","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1365-2141.2003.04220.x","article-title":"Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin\u2019s lymphoma or multiple myeloma","volume":"120","author":"Lincz","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2008.03.009_bib86","first-page":"159","article-title":"Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma","volume":"88","author":"Hishida","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2008.03.009_bib87","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood-2004-02-0557","article-title":"Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma","volume":"104","author":"Skibola","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib88","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2006-07-034330","article-title":"Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study","volume":"109","author":"Lim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib89","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","article-title":"Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases","volume":"14","author":"Salloum","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib90","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","article-title":"Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis","volume":"328","author":"Kamel","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib91","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-199610000-00015","article-title":"Hodgkin\u2019s disease and lymphoproliferations resembling Hodgkin\u2019s disease in patients receiving long-term low-dose methotrexate therapy","volume":"20","author":"Kamel","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib92","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI111388","article-title":"Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis","volume":"73","author":"Tosato","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2008.03.009_bib93","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2008.03.009_bib94","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM198111193052102","article-title":"Defective EBV-specific suppressor T-cell function in rheumatoid arthritis","volume":"305","author":"Tosato","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib95","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.blre.2008.03.009_bib96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib97","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","article-title":"Serious adverse events with infliximab: analysis of spontaneously reported adverse events","volume":"5","author":"Hansen","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2008.03.009_bib98","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib99","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2008.03.009_bib100","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(94)92150-4","article-title":"Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease","volume":"343","author":"Connell","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.03.009_bib101","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkin\u2019s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.blre.2008.03.009_bib102","first-page":"732","article-title":"Biologics in inflammatory disease: infliximab associated risk of lymphoma development","volume":"54","author":"Bucher","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.blre.2008.03.009_bib103","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","article-title":"Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn\u2019s disease: a cautionary tale?","volume":"13","author":"Rosh","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib104","first-page":"834","article-title":"Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy","volume":"6","author":"Sanli","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.blre.2008.03.009_bib105","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1080\/10428190701345433","article-title":"Hepatosplenic T-cell lymphoma in a patient with Crohn\u2019s disease who received infliximab therapy","volume":"48","author":"Zeidan","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2008.03.009_bib106","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/372560a0","article-title":"Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice","volume":"372","author":"Erickson","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.blre.2008.03.009_bib107","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis","volume":"64","author":"Feldmann","year":"1997","journal-title":"Adv Immunol"},{"key":"10.1016\/j.blre.2008.03.009_bib108","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/499054","article-title":"Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France","volume":"42","author":"Bonnet","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2008.03.009_bib109","doi-asserted-by":"crossref","unstructured":"Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823\u201330.","DOI":"10.1093\/jnci\/92.22.1823"},{"key":"10.1016\/j.blre.2008.03.009_bib110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00002030-200001280-00008","article-title":"B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin\u2019s lymphoma in people with AIDS","volume":"14","author":"Grulich","year":"2000","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib111","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1096-9896(199906)188:2<133::AID-PATH349>3.0.CO;2-Y","article-title":"Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern","volume":"188","author":"Delecluse","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib112","first-page":"2069","article-title":"Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas","volume":"54","author":"Shiramizu","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2008.03.009_bib113","first-page":"3561","article-title":"Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation","volume":"59","author":"Dean","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2008.03.009_bib114","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/eji.1830270729","article-title":"The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4","volume":"27","author":"D\u2019Apuzzo","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2008.03.009_bib115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2141.2006.06464.x","article-title":"Modern management of non-Hodgkin lymphoma in HIV-infected patients","volume":"136","author":"Mounier","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2008.03.009_bib116","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/CCO.0b013e3282c8c835","article-title":"HIV-associated lymphoma: the evidence for treating aggressively but with caution","volume":"19","author":"Sparano","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib117","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0145-2126(01)00113-8","article-title":"Multidrug resistance (MDR-1) expression in AIDS-related lymphomas","volume":"26","author":"Tulpule","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2008.03.009_bib118","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/BF02787345","article-title":"Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin\u2019s lymphoma","volume":"15","author":"Sparano","year":"1998","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib119","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-10-115659","article-title":"Immunological recovery in survivors following chemotherapy for AIDS related non Hodgkin\u2019s lymphoma","author":"Bower","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib120","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/00002030-200304110-00011","article-title":"Leptomeningeal disease in AIDS-related non-Hodgkin\u2019s lymphoma","volume":"17","author":"Sarker","year":"2003","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib121","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib122","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib123","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(00)02041-9","article-title":"High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma","volume":"355","author":"Gabarre","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.03.009_bib124","first-page":"1100","article-title":"High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease","volume":"89","author":"Gabarre","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2008.03.009_bib125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PAS.0b013e3180dc92d5","article-title":"KSHV\/HHV8 Doesn\u2019t Play a Significant Role in the Development of Plasmablastic Lymphoma of the Oral Cavity","volume":"32","author":"Carbone","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib126","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00001622-199609000-00007","article-title":"AIDS primary central nervous system lymphoma","volume":"8","author":"Flinn","year":"1996","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib127","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.V98.8.2339","article-title":"Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy","volume":"98","author":"Besson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib128","first-page":"199","article-title":"Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL)","volume":"9","author":"Raez","year":"1998","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.blre.2008.03.009_bib129","first-page":"346","article-title":"Primary CNS lymphoma","volume":"26","author":"Maher","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib130","first-page":"563","article-title":"The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features","volume":"18","author":"Johnson","year":"1997","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.blre.2008.03.009_bib131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-510X(98)00315-3","article-title":"HIV-associated primary CNS lymorbidity and utility of brain biopsy","volume":"163","author":"Skolasky","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.blre.2008.03.009_bib132","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/JCO.1999.17.2.554","article-title":"Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma","volume":"17","author":"Antinori","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib133","first-page":"1522","article-title":"Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography","volume":"11","author":"Castagna","year":"1997","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib134","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00002030-199714000-00009","article-title":"Intravenous methotrexate for primary central nervous system non-Hodgkin\u2019s lymphoma in AIDS","volume":"11","author":"Jacomet","year":"1997","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib135","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/cncr.20300","article-title":"Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients","volume":"100","author":"Newell","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2008.03.009_bib136","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/00002030-200111090-00007","article-title":"Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery","volume":"15","author":"Hoffmann","year":"2001","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib137","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/00002030-200205240-00020","article-title":"Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy","volume":"16","author":"Pajonk","year":"2002","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib138","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(97)09028-4","article-title":"Spectrum of AIDS-associated malignant disorders","volume":"351","author":"Goedert","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2008.03.009_bib139","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib140","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2003.01.096","article-title":"Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients","volume":"21","author":"Herida","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib141","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.blre.2008.03.009_bib142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002030-200301030-00011","article-title":"Improved survival in HIV-related Hodgkin\u2019s lymphoma since the introduction of highly active antiretroviral therapy","volume":"17","author":"Gerard","year":"2003","journal-title":"Aids"},{"key":"10.1016\/j.blre.2008.03.009_bib143","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.11459","article-title":"Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998","volume":"98","author":"Glaser","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2008.03.009_bib144","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdg408","article-title":"BEACOPP therapeutic regimen for patients with Hodgkin\u2019s disease and HIV infection","volume":"14","author":"Hartmann","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib145","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood-2002-03-0989","article-title":"Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection","volume":"100","author":"Spina","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib146","doi-asserted-by":"crossref","first-page":"10399","DOI":"10.1073\/pnas.1630810100","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile","volume":"100","author":"Jenner","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2008.03.009_bib147","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2401436","article-title":"Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas","volume":"13","author":"Fais","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2008.03.009_bib148","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.onc.1206270","article-title":"Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines","volume":"22","author":"Arguello","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2008.03.009_bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2007.06879.x","article-title":"KSHV\/HHV8-associated lymphomas","volume":"140","author":"Carbone","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2008.03.009_bib150","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0002-9440(10)64940-1","article-title":"Differential viral protein expression in Kaposi\u2019s sarcoma-associated herpesvirus-infected diseases: Kaposi\u2019s sarcoma, primary effusion lymphoma, and multicentric Castleman\u2019s disease","volume":"156","author":"Parravicini","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2008.03.009_bib151","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib152","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nm829","article-title":"A novel viral mechanism for dysregulation of beta-catenin in Kaposi\u2019s sarcoma-associated herpesvirus latency","volume":"9","author":"Fujimuro","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2008.03.009_bib153","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1568005033481222","article-title":"Targeted inhibition of angiogenic factors in AIDS-related disorders","volume":"3","author":"Aoki","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.blre.2008.03.009_bib154","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-06-028092","article-title":"Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling","volume":"109","author":"Sin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib155","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2002-07-2130","article-title":"Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma","volume":"101","author":"Aoki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib156","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1182\/blood-2004-07-2781","article-title":"Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis","volume":"105","author":"Prakash","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib157","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib158","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajh.10341","article-title":"Combined chemotherapy including high-dose methotrexate in KSHV\/HHV8-associated primary effusion lymphoma","volume":"73","author":"Boulanger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2008.03.009_bib159","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-08-2525","article-title":"Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B","volume":"101","author":"Ghosh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib160","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2006-06-031948","article-title":"Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph)","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib161","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/S0140-6736(05)66780-3","article-title":"Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin\u2019s lymphoma","volume":"365","author":"Diepstra","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2008.03.009_bib162","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa023141","article-title":"Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis","volume":"349","author":"Hjalgrim","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2008.03.009_bib163","first-page":"154","article-title":"Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography","volume":"16","author":"Guzowski","year":"2005","journal-title":"J Biomol Tech"},{"key":"10.1016\/j.blre.2008.03.009_bib164","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(05)70434-4","article-title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium","volume":"7","author":"Rothman","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2008.03.009_bib165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.gene.6364337","article-title":"Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk","volume":"7","author":"Nieters","year":"2006","journal-title":"Genes Immun"},{"key":"10.1016\/j.blre.2008.03.009_bib166","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1158\/0008-5472.CAN-06-4752","article-title":"Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2008.03.009_bib167","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood.V91.10.3574","article-title":"Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin\u2019s lymphoma outcome","volume":"91","author":"Warzocha","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib168","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2003-06-1850","article-title":"Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma","volume":"103","author":"Lech-Maranda","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib169","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2005-01-026690","article-title":"Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes","volume":"108","author":"Hill","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib170","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1055-9965.787.13.5","article-title":"Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma in adults","volume":"13","author":"Gemmati","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.blre.2008.03.009_bib171","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-4608(03)00185-7","article-title":"Polymorphism in the hMSH2 gene (gIVS 12-6T\u2013>C) and risk of non-Hodgkin lymphoma in a Japanese population","volume":"147","author":"Hishida","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.blre.2008.03.009_bib172","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00439-006-0177-2","article-title":"Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut","volume":"119","author":"Shen","year":"2006","journal-title":"Hum Genet"},{"key":"10.1016\/j.blre.2008.03.009_bib173","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2008.03.009_bib174","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1349-7006.2000.tb00909.x","article-title":"The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(\u2212) cases in Japanese population","volume":"91","author":"Kuze","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.blre.2008.03.009_bib175","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2007-01-067769","article-title":"The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X08000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X08000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T23:05:40Z","timestamp":1708902340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X08000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":175,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0268960X08000349"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2008.03.009","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}